Overview

Sitagliptin and Glucagon Counterregulation

Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the effect of DPP-4 inhibition on glucagon counter-regulatory mechanisms at moderate hypoglycemia in metformin-treated subjects with T2DM
Phase:
Phase 4
Details
Lead Sponsor:
Lund University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Glucagon
Sitagliptin Phosphate